Tranzyme Pharma to Present at the Seventh Annual JMP Securities Healthcare Conference in New York

RESEARCH TRIANGLE PARK, N.C., June 26, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Franck S. Rousseau, M.D., Chief Medical Officer, will present at the Seventh Annual JMP Securities Healthcare Conference taking place at The Peninsula in New York, N.Y. July 12-13, 2012. Dr. Rousseau is scheduled to speak on Friday, July 13, 2012 at 1:00 pm ET.

About Tranzyme Pharma

Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. This product candidate targets a significant underserved market. Enrollment in a multinational, Phase 2b trial is ongoing; top-line data are expected by year-end 2012. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company's web site at www.tranzyme.com.

CONTACT: Corporate Inquiries:

         Susan Sharpe

         Director, Corporate Communications

         (919) 328-1109

         ssharpe@tranzyme.com

         

         Investor Inquiries:

         David Carey

         Lazar Partners, Ltd.

         (212) 867-1768

         dcarey@lazarpartners.com

Close window | Back to top

• delicious
• Digg
• Facebook
• LinkedIn
• Mixx
• Twitter
• Yahoo! Buzz